Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 15/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990731 | 0.78 | ADORA1 (0.54) | ADORA1ADORA2AKMT2A | |
| SCHEMBL2836957 | 0.76 | KDM4E (0.53) | ADORA1ADORA2A | |
| SCHEMBL3282400 | 0.76 | ADORA1 (0.62) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL10205892 | 0.76 | NTRK1 (0.58) | ADORA1ADORA2ANTRK1 | |
| SCHEMBL3284087 | 0.76 | ADORA1 (0.53) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL4582424 | 0.76 | ADORA1 (0.83) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL11077623 | 0.76 | ADORA1 (0.53) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL29177828 | 0.74 | ADORA1 (0.51) | ADORA1ADORA2AKMT2A | |
| Ammonia Solution, Strong SCHEMBL28877790 | 0.74 | ADORA1 (0.81) | ADORA1ADORA2AGFERKMT2A | |
| SCHEMBL19347664 | 0.73 | ADORA1 (0.54) | ADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024339-B1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI SA (FR) | 2013-04-10 | — | — | EP | disclosed |
| US-7709494-B2 | for lowering blood glucose, treating diabetes, or increasing insulin release, hyperglycemia; (1S,3R)-3-(4,5-Diphenylpyrimidin-2-yloxymethyl)cyclohexanecarboxylic acid | SANOFI-AVENTIS (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709494-B2 | for lowering blood glucose, treating diabetes, or increasing insulin release, hyperglycemia; (1S,3R)-3-(4,5-Diphenylpyrimidin-2-yloxymethyl)cyclohexanecarboxylic acid | SANOFI-AVENTIS (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20090149486-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-06-11 | — | — | US | disclosed |
| CN-101421249-A | 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (FR) | 2009-04-29 | — | — | CN | disclosed |
| CN-101421249-A | 4,5-diphenyl-pyrimidinyl-oxy or -mercapto substituted carboxylic acids, method for the production and use thereof as medicaments | SANOFI AVENTIS DEUTSCHLAND (FR) | 2009-04-29 | — | — | CN | disclosed |
| EP-2024339-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2009-02-18 | — | — | EP | disclosed |
| EP-2024339-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis (FR) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007131619-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007131619-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI-AVENTIS (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149486-A1 | 4,5-DIPHENYL-PYRIMIDINYL-OXY OR -MERCAPTO SUBSTITUTED CARBOXYLIC ACIDS, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SLC5A1, SLC5A2, DPP4 | ADORA1 1110/4885ADORA2A 1648/4885GFER 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.